A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

PHASE3CompletedINTERVENTIONAL
Enrollment

898

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

December 31, 2017

Conditions
Migraine Disorders
Interventions
DRUG

ALD403

DRUG

Placebo

Trial Locations (87)

10312

Research Site, Staten Island

10530

Research Site, Hartsdale

11213

Research Site, Brooklyn

11229

Research Site, Brooklyn

14609

Research Site, Rochester

15478

Research Site, Smithfield

18104

Research Site, Allentown

23294

Research Site, Richmond

23454

Research Site, Virginia Beach

27265

Research Site, High Point

27405

Research Site, Greensboro

27713

Research Site, Durham

28401

Research Site, Wilmington

29621

Research Site, Anderson

30281

Research Site, Stockbridge

30331

Research Site, Atlanta

30342

Research Site, Atlanta

32720

Research Site, DeLand

32751

Research Site, Maitland

32801

Research Site, Orlando

33009

Research Site, Hallandale

33012

Research Site, Hialeah

33143

Research Site, Miami

33155

Research Site, Miami

33173

Research Site, Miami

33351

Research Site, Sunrise

33880

Research Site, Winter Haven

33912

Research site, Fort Myers

34102

Research Site, Naples

34201

Research Site, Bradenton

35216

Research Site, Birmingham

37404

Research Site, Chattanooga

37421

Research Site, Chattanooga

37660

Research Site, Kingsport

38119

Research Site, Memphis

39232

Research Site, Flowood

40509

Research Site, Lexington

42303

Research Site, Owensboro

45424

Research Site, Dayton

48104

Research Site, Ann Arbor

48334

Research Site, Farmington Hills

49201

Research Site, Jackson

55402

Research Site, Minneapolis

60532

Research Site, Lisle

60607

Research Site, Chicago

63141

Research Site, St Louis

65807

Research Site, Springfield

66206

Research Site, Prairie Village

70115

Research Site, New Orleans

72205

Research Site, Little Rock

73034

Research Site, Edmond

73069

Research Site, Norman

73112

Research Site, Oklahoma City

75231

Research Site, Dallas

77074

Research Site, Houston

77081

Research Site, Houston

78745

Research Site, Austin

80528

Research Site, Fort Collins

80918

Research Site, Colorado Springs

85013

Research Site, Phoenix

85712

Research Site, Tucson

87102

Research Site, Albuquerque

89119

Research Site, Las Vegas

89502

Research Site, Reno

90404

Research Site, Santa Monica

90806

Research Site, Long Beach

91403

Research Site, Sherman Oaks

91763

Research Site, Montclair

92056

Research Site, Oceanside

92103

Research Site, San Diego

92108

Research Site, San Diego

92374

Research Site, Redlands

92801

Research Site, Anaheim

92835

Research Site, Fullerton

93702

Research Site, Fresno

97210

Research Site, Portland

98007

Research Site, Bellevue

06905

Research Site, Stamford

06708

Research Site, Waterbury

02131

Research Site, Boston

02760

Research Site, North Attleboro

01104

Research Site, Springfield

02472

Research Site, Watertown

0112

Research Site, Tbilisi

0160

Research Site, Tbilisi

0179

Research Site, Tbilisi

0186

Research Site, Tbilisi

Sponsors
All Listed Sponsors
lead

Alder Biopharmaceuticals, Inc.

INDUSTRY

NCT02559895 - A Multicenter Assessment of ALD403 in Frequent Episodic Migraine | Biotech Hunter | Biotech Hunter